PTx treatment did not affect MCF10A proliferation in 2D culture but inhibited proliferation of several HER2+ breast cancer cell lines, including Neu, MCF10A/HER2, BT474, and BT474R, a trastuzumab-resistant BT474 derivative (Figure 2, I–M). Here, ERBB2 is linked to breast carcinoma.